title: Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects.
abstract: OBJECTIVE
  To evaluate the effect of steady-state bupropion SR sustained-release (BUP) on the pharmacokinetics of a single 100-mg dose of lamotrigine (LTG).
  
  
  METHODS
  Randomized, open-label, two-way crossover study
  
  
  METHODS
  Clinical Studies Ltd., Fort Lauderdale, Florida.
  
  
  METHODS
  Twelve healthy subjects.
  
  
  METHODS
  Treatment A: LTG 100 mg with steady-state BUP 150 mg twice/day; treatment B: LTG 100 mg.
  
  
  RESULTS
  The pharmacokinetics of LTG were determined by noncompartmental methods using plasma and urine concentrations. Geometric least squares mean ratios and 90% confidence intervals were calculated for treatment comparison. Safety assessments included clinical laboratory tests, vital signs, and adverse events monitoring. Pharmacokinetic parameters of LTG were not significantly different between treatments. Five subjects experienced seven mild, potentially drug-related adverse events (insomnia [2]; nausea, headache, facial pain, fatigue, and depression [1 each]) that resolved spontaneously.
  
  
  CONCLUSIONS
  Steady-state BUP caused no clinically relevant changes in the pharmacokinetics of a single dose of LTG.
authors.affiliation: Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, USA.
authors.forename: J
authors.initials: J
authors.lastname: Odishaw
authors.forename: C
authors.initials: C
authors.lastname: Chen
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics*; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D016642:Bupropion / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D014227:Triazines / Q000009:adverse effects / Q000493:pharmacokinetics*
chemical_list: D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D014227:Triazines; D016642:Bupropion; D000077213:Lamotrigine